TCM Pharmaceutical Company Files Hong Kong IPO Application, Leads Local Market With 9.2% Share on July 17

According to Hong Kong Stock Exchange disclosure on July 17, Bao Ji Yuan He (TCM) Limited submitted a main board IPO application with Huafu Juye Enterprise Finance as sole sponsor. The Hong Kong-based Chinese medicine pharmaceutical group ranks first in Hong Kong's traditional Chinese medicine market with 9.2% share by 2025 terminal market sales, per Frost & Sullivan.

The company operates a vertically integrated model combining branded Chinese medicine products and TCM clinics. As of March 31, 2026, it operates 40 clinics staffed by over 50 registered Chinese medicine practitioners. Revenue reached 464 million Hong Kong dollars in the fiscal year ended March 31, 2026, up from 361 million Hong Kong dollars in the prior year, with net profit of 80.9 million Hong Kong dollars.